Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1 Diabetes by Murphy, Helen R. et al.
Closed-Loop Insulin Delivery During
Pregnancy Complicated by Type 1
Diabetes
























OBJECTIVE—This study evaluated closed-loop insulin delivery with a model predictive con-
trol (MPC) algorithm during early (12–16 weeks) and late gestation (28–32 weeks) in pregnant
women with type 1 diabetes.
RESEARCHDESIGNANDMETHODS—Tenwomenwithtype1diabetes(age31years,
diabetes duration 19 years, BMI 24.1 kg/m
2, booking A1C 6.9%) were studied over 24 h during
early (14.8 weeks) and late pregnancy (28.0 weeks). A nurse adjusted the basal insulin infusion
rate from continuous glucose measurements (CGM), fed into the MPC algorithm every 15 min.
Mean glucose and time spent in target (63–140mg/dL), hyperglycemic (.140to $180mg/dL),
and hypoglycemic (,63 to #50 mg/dL) were calculated using plasma and sensor glucose mea-
surements. Linear mixed-effects models were used to compare glucose control during early and
late gestation.
RESULTS—During closed-loop insulin delivery, median (interquartile range) plasma glucose
levelswere117(100.8–154.8)mg/dLinearlyand126(109.8–140.4)mg/dLinlategestation(P=
0.72). The overnight mean (interquartile range) plasma glucose time in target was 84% (50–
100%)inearlyand100%(94–100%)inlatepregnancy(P=0.09).Overnightmean(interquartile
range)time spent hyperglycemic (.140mg/dL)was7%(0–40%) inearlyand 0%(0–6%)inlate
pregnancy (P = 0.25) and hypoglycemic (,63 mg/dL) was 0% (0–3%) and 0% (0–0%), respec-
tively (P = 0.18). Postprandial glucose control, glucose variability, insulin infusion rates, and
CGM sensor accuracy were no different in early or late pregnancy.
CONCLUSIONS—MPCalgorithmperformancewasmaintainedthroughoutpregnancy,sug-
gesting that overnight closed-loop insulin delivery could be used safely during pregnancy. More
work is needed to achieve optimal postprandial glucose control.
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F
or women with type 1 diabetes, self-
management is particularly chal-
lenging during the physiologic and
hormonal changes of pregnancy. These
contribute to extremely labile glucose
levels in early pregnancy and progressive
insulin resistance with advancing gesta-
tion (1). Continuous glucose monitoring
(CGM) studies indicate that pregnant
women with type 1 diabetes spend an av-
erageof10hdailywithglucoselevelsout-
side the recommended target (63–140
mg/dL) even with apparently safe A1C
levels (2). Hence, their pregnancy out-
comes remain suboptimal, with increased
risks both of adverse pregnancy outcome
(congenital malformation, stillbirth, neo-
natal death) and of perinatal morbidity
(preterm delivery, macrosomia, neonatal
care admission) (3,4).
Strict glycemic control targets are
more readily achievable by pregnant
women with type 2 diabetes, with recent
studies demonstrating improvements
both in adverse pregnancy outcome and
in perinatal morbidity (5). In contrast,
there has been a disappointing lack of
progress in type 1 diabetes, most likely
d u et oam o r es e v e r eg l y c e m i cd i s t u r -
bance (6). Hence, despite educational
(structured education and prepregnancy
care programs) and technologic advances
(fast-acting insulin analogs, insulin pump
therapy), suboptimal glycemic control
and poor pregnancy outcomes persist
(7–9).
Insulin pump therapy, CGM, and
sensor-augmented pump therapy have
beenshowntofacilitateimprovedglycemic
control in nonpregnant individuals
(10–12). However, despite evidence sup-
portingCGMinpregnancy,thebeneﬁtsof
insulin pump therapy are not well estab-
lished, particularly during late pregnancy
(13–15). This may be due to difﬁculties
responding to the physiologic challenges
of pregnancy, such as changes in gastric
emptying, gluconeogenesis, and insulin
kinetics (16).
Closed-loop systems use a control
algorithm to link insulin delivery with
real-timeCGMmeasurements(17).Over-
night use improved glucose control and
reduced hypoglycemia in children with
type 1 diabetes (18). A closed-loop sys-
tem with physiologically responsive insu-
lin adjustments capable of maintaining
near-normal glucose levels could be of
great beneﬁt for pregnant women with
type 1 diabetes.
Obstacles to developing closed-loop
systems in pregnancy include a lack of
sensor accuracy data and no data regard-
ing performance of control approaches
such as the model predictive control
(MPC) algorithm. Previous studies docu-
mented clinically acceptable accuracy of
real-time CGM outside of pregnancy but
have compared only retrospective CGM
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ORIGINAL ARTICLEand capillary glucose levels during preg-
nancy (15,19). No studies have evaluated
sensor accuracy with plasma glucose
measurements during pregnancy.
Before outpatient closed-loop studies
can proceed, they must be supported by
scientiﬁcally rigorous data on the safety
and efﬁcacy of the real-time CGM and the
control algorithm to function throughout
the physiologic changes of pregnancy.
The aim of this study was to evaluate the
performance of the FreeStyle Navigator
CGM and MPC control algorithm during
early (12–16 weeks) and late gestation
(28–32 weeks).
RESEARCH DESIGN AND
METHODS—Study protocols were ap-
proved by the research ethics committee,
and participants provided written in-
formed consent.
Participants
From March 2009 to March 2010, 10
pregnant women with type 1 diabetes
from three U.K. antenatal diabetes clinics
(Cambridge n =7 ,N o r w i c hn =2 ,a n d
Ipswich n = 1) were recruited into studies
to develop closed-loop systems for use in
pregnancy. Inclusion criteria were type 1
diabetes (World Health Organization cri-
teria) for at least 12 months before preg-
nancy,intensiveinsulintherapy(multiple
daily injections or pump), and a viable
singleton pregnancy with gestational
age conﬁrmed by ultrasound imaging.
W o m e nw i t hp o o rg l y c e m i cc o n t r o l
(A1C .10%), signiﬁcant obesity (BMI
$35kg/m
2),insulinresistance(totaldaily
insulin dose $1.5 units/kg), nephropa-
thy, autonomic neuropathy, or gastro-
paresis were excluded.
Study protocol
All participants were admitted to the Well-
come Trust Clinical Research Facility
(Cambridge, U.K.) for 24 h on two occa-
sions: once during early pregnancy (12–16
weeks) and again during later pregnancy
(28–32 weeks).
Study devices and procedures
The day before each study, a FreeStyle
Navigator sensor with a 10-h run-in
calibration period (Abbott Diabetes
C a r e ,A l a m e d a ,C A )w a si n s e r t e di n t o
the upper arm and calibrated with capil-
lary glucose measurements according to
the manufacturer’s instructions. For ﬁve
women who required multiple daily in-
jections, basal insulin was withdrawn
24 h before admission and replaced with
rapid-acting insulin aspart (Novo Nordisk,
Bagsvaerd, Denmark).
Patientsarrivedat theresearchfacility
at 1300 h and an intravenous sampling
cannula was inserted. Women were con-
nected to an insulin pump (Deltec
Cozmo, Smiths Medical, St. Paul, MN)
delivering insulin aspart. From 1400 h,
venous samples were obtained every
15 min for plasma glucose concentration
measured by the Yellow Springs Instru-
ment analyzer (YSI2300 STAT Plus Ana-
lyzer, Farnborough, U.K.). At 1800 h,
women ate a standardized evening meal
of pasta with tomato-based vegetable
sauce (602 Kcal, 80 g carbohydrate
[50%], 9 g protein [31%], 4 g fat [15%]).
They fasted overnight and ate a standard-
ized breakfast of orange juice and toast
with jam (356 Kcal; 60 g carbohydrate
[60%], 11 g fat [28%], 7.6 g protein [8%])
at 0700 h the following morning. Prandial
insulin doses were calculated according to
the women’s insulin/carbohydrate ratio
and capillary glucose levels. The study
ended at 1200 h.
MPC algorithm
The MPC algorithm calculated the basal
insulin infusion rates. It was manually
adjusted at 15-min intervals by a research
nurse from 1400 to 1200 h the following
day. It was initialized using women’s
weight, basal insulin requirements, and
totaldailyinsulindoseduring thepreced-
ing3days.Forwomenwhorequiredmul-
tiple daily injections, the total daily
insulindose was reducedby30%forcon-
version to pump therapy.
Sensor glucose measurements were
used to update two model parameters: an
endogenous glucose ﬂux correcting for
Figure 1—Plasma glucose concentrations and insulin infusion rates are shown during early and
late gestation. The dark lines represent the median plasma glucose levels and insulin infusion
rates during early pregnancy (visit 1, 14.8 weeks) and the lighter lines during late pregnancy
(visit 2, 28.0 weeks). On both visits, a standardized dinner (80 g carbohydrate) was eaten at
1800, followed by an overnight fast until breakfast (60 g carbohydrate) at 0700 h the next
morning.Prandialinsulinboluseswerecalculatedaccordingtothewomen’sinsulin-carbohydrate
ratio and capillary ﬁngerstick glucose levels. Basal insulin infusion rates were calculated using
CGM sensor glucose values and the MPC algorithm.
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carbohydrate bioavailability. Several com-
peting models differing in the rates of
subcutaneous insulin absorption and car-
bohydrate absorption were run in parallel.
A combined model forecasted plasma glu-
cose excursions over a 2.5-h prediction
horizon. Infusion rates were calculated
to achieve a sensor glucose target of 104.4
mg/dL, with safety rules including a pre-
deﬁnedmaximalbasalinsulininfusionrate
to prevent overdosing and ﬂexibility to
increase the target to 131.4 mg/dL if pre-
vious predictions were inaccurate. Plasma
glucose levels were available for safety
purposes, but only sensor glucose levels
were fed into the algorithm.
Statistical analysis
Power calculations were not performed
because this was an exploratory safety
study. The sample size was pragmatic,
based on data in human pregnancy, doc-
umentingincreasedgestationalgluconeo-
genesis in seven women (16). Mean
glucose, time spent in target (National In-
stitute for Health and Clinical Excellence
recommended range, 63–140 mg/dL)
(20), time spent below target (,63 and
#50 mg/dL), time spent above target
(.140 and $180 mg/dL), and insulin in-
fusion rate were calculated for each visit
using plasma and sensor glucose mea-
surements. Glucose control measures
were calculated from 1800 h, reﬂecting
that ittakes4hforclosed-looptobecome
effective.
Because many variables were not
normally distributed, the Wilcoxon non-
parametric test was used to compare the
twostudyperiods.Separateanalyseswere
conducted of the periods after dinner
(1800–2300 h), overnight (2300–0700 h),
and after breakfast (0700–1200 h). Values
are given as median (interquartile range).
Linear mixed-effects models were
applied to the glucose measurements.
Participants were treated as random ef-
fects, and gestational age (early or late
pregnancy), time of day (after dinner,
overnight, after breakfast) as ﬁxed effects.
The correlation structure of repeated glu-
cosemeasurementswithineachstudywas
modeled using a Box-Jenkins model with
two parameters for the autocorrelation
and two parameters for the moving aver-
age; namely, an autoregressive moving
average (2,2) model. Maximum likeli-
hood algorithms were used to estimate
parameters. The hypothesis of interest
was whether glucose levels showed sys-
tematic differences between early and late
pregnancy across subjects, tested with
likelihood ratio tests. Analyses were con-
ducted on SPSS v15 software (SPSS Inc.,
Chicago, IL) and on R v2 11.1 (Free
Software Foundation, Boston, MA).
Sensor accuracy was evaluated
throughout the study (1400–1200 h) as
t h er e l a t i v ea b s o l u t ed i f f e r e n c eb e t w e e n
sensor glucose and paired plasma glucose
divided by plasma glucose and by Clarke
error-grid analysis (21). Grade “A+B” as-
sessed sensor efﬁcacy and grade “D+E”
assessed sensor safety. Low blood glucose
index was calculated as an average of
transformed glucose measurements pro-
gressively increasing at low glucose levels
and assessed the duration and extent of
hypoglycemia.
RESULTS—Participants were a median
(interquartile range) age of 31.1 (28.7–
31.7) years, had a diabetes duration of
19 (13.5–24) years, a weight of 66.6
(64–73.9) kg, a booking A1C of 6.9%
(6.2–8.0), and a BMI of 24.1 (23.1–
26.3) kg/m
2. Individual characteristics
and gestational changes in A1C, weight,
a n di n s u l i nd o s e sa r es h o w ni nt h e
Supplementary Data. Comparing the
early (14.8 weeks) and late (28.0 weeks)
gestation visits, there were no signiﬁcant
differencesbetween plasma glucose levels
(in mg/dL) at study commencement
(118.8 [95.4–156.6] and 102.6 [75.6–
140.4; P = 0.5]), or throughout the study
(117 [100.8–154.8] and 126 [109.8–
140.4; P = 0.72]). Plasma glucose levels
and insulin infusion rates are shown in
Fig. 1.
Comparison of overnight glucose
control in early and late pregnancy
The level of overnight glucose control
achieved during closed-loop insulin de-
livery is summarized in Table 1. The time
spent with plasma glucose level within
the target of 63 to 140 mg/dL was 84%
(50–100%) in early pregnancy and 100%
(94–100%) in late pregnancy (P = 0.09).
Differencesbetweentimespentbelowtar-
get(,63or#50mg/dL)duringearlyand
late pregnancy were not statistically sig-
niﬁcant.Therewere noepisodes of symp-
tomatic nocturnal hypoglycemia. There
was one episode of unexplained hypogly-
cemia documented as CGM glucose of 63
mg/dL and plasma glucose of 46.8 mg/dL
at 0500 h in early pregnancy, despite an
infusion of only 0.4 units of basal insulin
during the preceding 6 h (0.066 units/h).
The time spent hyperglycemic(.140
mg/dL) was 7% (0–40%) in early preg-
nancy and 0% (0–6%) in late pregnancy
(P = 0.25). There were no overnight epi-
sodes of hyperglycemia $180 mg/dL.
Glucose variability assessed by the stan-
dard deviation of plasma glucose was un-
changed,aswasthemeaninsulininfusion
rate and standard deviation of the insulin
infusion in early and late pregnancy.
Table 1—Overnight glucose control using FreeStyle Navigator continuous glucose monitor
and the MPC algorithm in women with type 1 diabetes during early and late pregnancy
Variable Early pregnancy Late pregnancy P value
Median plasma glucose, mg/dL
At start of night (2300 h) 102.6 (100.8–142.2) 113.4 (86.4–122.4) 0.51
Overnight (2300–0700 h) 109.8 (82.8–131.4) 109.8 (99–113.4) 0.57
SD overnight plasma glucose 14.4 (10.8–21.6) 16.2 (12.6–23.4) 0.28
Time in target (63–140 mg/dL), % 84 (50–100) 100 (94–100) 0.09
Nocturnal hypoglycemia
% Time hypoglycemic ,63 mg/dL 0 (0–3) 0 (0–0) 0.18
% Time hypoglycemic #50 mg/dL* 0 (0–0) 0 (0–0) 0.32
Nocturnal hyperglycemia
% Time hyperglycemic .140 mg/dL 7 (0–40) 0 (0–6) 0.25
% Time hyperglycemic $180 mg/dL 0 (0–0) 0 (0–0) 0.32
Blood glucose index
Low 0.9 (0.0–4.3) 1.1 (0.2–2.7) 0.80
High 0.3 (0.0–1.3) 0.2 (0.1–0.5) 0.51
Mean insulin infusion, units/kg 0.5 (0.4–0.8) 0.6 (0.4–1.1) 0.80
SD insulin infusion rate 0.5 (0.4–0.6) 0.6 (0.5–0.7) 0.11
Values are given as median (interquartile range). *There was one episode of unexplained nocturnal hypo-
glycemiainearly pregnancy(CGMglucose 63mg/dL,plasmaglucose46.8mg/dL)at0500hdespiteonly0.4
units of basal insulin infused during the preceding 6 h (insulin infusion rate 0.066 units/h).
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Postprandial glucose control in
early and late pregnancy
There were no differences in the pre- and
postprandial glucose levels for the even-
ing meal or breakfast in early and late
pregnancy (Table 2). After 4 h of closed-
loop insulin delivery, plasma glucose
levels were 88.2 (68.4–127.8) mg/dL in
early and 73.8 (64.8–82.8) mg/dL in late
pregnancy (P = 0.14). After a large even-
ing meal (80 g carbohydrate), for which
women decided their own prandial insu-
lin dose, the time spent with plasma
glucose levels in target was 68% (61–
97%) in early and 77% (58–93%) in late
pregnancy (P = 0.51). There were no sig-
niﬁcant changes in the time spent hypo-
glycemic or hyperglycemic, with 13%
(0–39%) time spent hyperglycemic in
early pregnancy compared with 5%
(0–41%) in late pregnancy (P =0 . 2 4 ) .
The fasting plasma glucose levels
were 109.8 (95.4–126) mg/dL and
118.8 (102.6–133.2) mg/dL in early and
late pregnancy (P = 0.14). After a 60-g
carbohydrate breakfast, the postprandial
glucose levels, time in target, glucose var-
iability, and insulin infusion rates and
variability were not statistically different
in early or late gestation. However, less
time was spent with plasma glucose
within the target range after breakfast—
59% (40–74%) early and 47% (39–77%)
late pregnancy—and more time spent
hyperglycemic after breakfast—28%
(20–58%) early and 44% (10–55%) late
pregnancy—comparedwiththeafterdin-
n e ro ro v e r n i g h tp e r i o d s .
CGM sensor accuracy
Sensor accuracy, evaluated as the mean
absolute relative difference between sen-
sor glucose and paired plasma glucose
divided by plasma glucose, was 13.3%
(14.7% in early vs. 11.9% in late preg-
nancy;P=0.15).Medianabsoluterelative
differences were 11.4% (12.8% in early
vs. 9.9% in late pregnancy; P = 0.21). Ac-
cording to Clarke error grid analysis
(EGA), 93.6% values in early and 95.6%
in late pregnancy were clinically accept-
able(zonesA+B),withnoovercorrection
errors or unsafe control (Table 3).
CONCLUSIONS—Here we demon-
strate clinically and statistically accept-
able accuracy of the FreeStyle Navigator
CGM and MPC algorithm in women with
type 1 diabetes during pregnancy.
Closed-loop insulin delivery was associ-
ated with nearly normoglycemia over-
night, both in early and in late pregnancy,
suggesting that the MPC algorithm safely
adapts insulin delivery for advancing
gestational age.
Sensingerrorshavebeenconsidereda
major obstacle to effective closed-loop
systems.Thisrepresents aparticularchal-
lenge given the narrow glucose reference
range and risk of hypoglycemia during
pregnancy. Despite tighter glycemic tar-
gets, sensor accuracy in this study was
comparable to previously published data
(19). As in nonpregnant individuals, ac-
curacy was greatest for glucose levels
within and above the target range and
least for glucose levels #70 mg/dL. The
MPC algorithm compensated for discrep-
ancies between the sensor and reference
glucose level during hypoglycemia by
suspending insulin delivery when sensor
glucose values fell ,80 mg/dL.
Despite this safety barrier, there was
one episode of unexplained asymptom-
atichypoglycemiaat 0500h,which could
not be attributed to sensor discrepancy or
to the MPC advice, because only 0.4 units
of insulin was infused over the preceding
6 h. Considered in the context of con-
ventional treatment, whereby women
with type 1 diabetes spend on average
16.2% overnight (1.3 h) hypoglycemic
during pregnancy (2) and assuming this
Table 2—Pre- and postprandial glucose control with prandial insulin boluses calculated
by women according to insulin/carbohydrate ratio and ﬁngerstick glucose values
Variable Early pregnancy Late pregnancy P value
Before and after 80-g carbohydrate Ć
evening meal
Plasma glucose at start
(1400 h), mg/dL 118.8 (95.4–149.4) 102.6 (75.6–140.4) 0.5
Plasma glucose pre-evening meal
(1800 h), mg/dL 88.2 (68.4–127.8) 73.8 (64.8–82.8) 0.14
Median postprandial plasma glucose
(1800–2300 h), mg/dL 104.4 (100.8–136.8) 108 (82.8–135) 0.20
SD plasma glucose 25.2 (14.4–32.4) 19.8 (18–25.2) 0.24
%T i m ei nt a r g e t( 6 3 –140 mg/dL) 68 (61–97) 77 (58–93) 0.51
% Time hypoglycemic ,63 mg/dL 0 (0–8) 3 (0–18) 0.46
% Time hypoglycemic ,50 mg/dL 0 (0–0) 0 (0–0) 0.65
% Time hyperglycemic .140 mg/dL 13 (0–39) 5 (0–41) 0.24
% Time hyperglycemic .180 mg/dL 0 (0–2) 0 (0–0) 0.18
Blood glucose index
Low 1.2 (0.1–2.0) 1.2 (0.5–6.3) 0.44
High 0.7 (0.0–2.2) 0.3 (0.0–1.7) 0.17
Mean insulin infusion, units/kg 0.5 (0.3–0.6) 0.6 (0.2–0.9) 0.96
SD insulin infusion rate 0.5 (0.4–0.7) 0.6 (0.4–0.9) 0.72
Before and after 60-g carbohydrate
breakfast
Fasting plasma glucose (0700 h) 109.8 (95.4–126) 118.8 (102.6–133.2) 0.14
Median postprandial plasma glucose
(0700–1200 h), mg/dL 117 (100.8–154.8) 126 (109.8–140.4) 0.72
SD plasma glucose 32.4 (18.0–41.4) 34.2 (21.6–48.6) 0.80
%T i m ei nt a r g e t( 6 3 –140 mg/dL) 59 (40–74) 47 (39–77) 0.88
% Time hypoglycemic ,63 mg/dL 1 (0–23) 1 (0–18) 1.0
% Time hypoglycemic ,50 mg/dL 0 (0–0) 0 (0–1) 0.18
% Time hyperglycemic .140 mg/dL 28 (20–58) 44 (10–55) 0.86
% Time hyperglycemic .180 mg/dL 0 (0–25) 3 (0–24) 0.83
Blood glucose index
Low 1.2 (0.2–5.5) 1.5 (0.1–3.7) 0.80
High 1.2 (0.8–5.6) 2.1 (0.4–4.3) 0.96
Mean insulin infusion, units/kg 0.3 (0.2–0.9) 0.5 (0.3–1.0) 0.24
SD insulin infusion rate 0.7 (0.2–1.0) 0.5 (0.1–1.3) 0.88
Values are given as median (interquartile range).
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suggests potential safety beneﬁts of
closed-loop insulin delivery. Note that
in this proof of concept study, we did
not modify the algorithm to distinguish
between pre- and postprandial glucose
targets and that even tighter glycemic
thresholds (60–99 fasting and ,130after
meals) may be required for optimal fetal
growth.
Nocturnal hyperglycemia was mini-
mized in women requiring established
continuous subcutaneous insulin infu-
sion as well as in those using multiple
daily injections. This also compares fa-
vorably with previous CGM studies de-
scribing36.4%timehyperglycemic(2.9h
.140, 1.0 h .200 mg/dL) (2).
Thelevelofovernight glucose control
obtained during early and late gestation
was similar to that recently obtained in
children and adults with type 1 diabetes
(18).Our grouphasshownthatusingoff-
the-shelf sensors and earlier versions of
this MPC algorithm, children achieved
53% (48–57%) overnight time in target
aftereatingalarge,rapidlyabsorbedeven-
ing meal and 55% (37–64%) after a large,
slowly absorbed meal (18). Adults using
closed-loop did even better, spending
72 6 15% overnight time in target
after a large evening meal (100 g carbohy-
drate)andgenerousalcoholconsumption
(0.75 g/kg ethanol) (22). These studies
suggest potential superiority of overnight
closed-loop insulin delivery over conven-
tional pump therapy outside pregnancy.
The difference between conventional
and close-loop insulin delivery is the
ability of the latter to rapidly respond to
glucose excursions, with more variability
of the insulin infusion rates despite com-
parable overall insulin doses. In our
current study, the MPC algorithm was
able to safely increase the insulin infusion
rates for advancing gestational age, based
on the women’s weight and total daily in-
sulin dose.
This study also illustrates the chal-
lenges of postprandial hyperglycemia,
particularly after a high-carbohydrate
breakfast. After nearly optimal overnight
control, women had more glucose vari-
ability and spent more time hyperglyce-
mic after breakfast compared with after
dinner. Despite apparently more pro-
longed hyperglycemia after breakfast in
late pregnancy (Fig. 1), differences in the
time spent hyperglycemic between early
and late pregnancy (28% in early and
44% in late gestation) did not reach sta-
tistical signiﬁcance, most likely due to
the small sample size and intraindividual
variability.
There were also no signiﬁcant differ-
ences in the insulin infusion rates (when
corrected for maternal weight) in early
and late gestation. However, there is a
trend to higher glucose levels at various
points in later pregnancy, after starting
at a lower glucose, and a trend to an
increased average insulin infusion rate.
The latter would be expected given the
increasinginsulinresistanceofpregnancy
and with larger numbers may have
reached statistical signiﬁcance.
We now plan to perform randomized
controlled studies of closed-loop insulin
deliverywithtighterglycemictargets,ﬁrst
in the hospital and then over multiple
nights in the home setting. To evaluate
clinical effectiveness of closed-loop insu-
lin delivery, a large, multicenter random-
ized study comparing closed-loop with
sensor-augmented pump therapy will be
needed. Meanwhile, the MPC safety and
sensor accuracy data from this study pave
the way for future research to reﬁne
closed-loop insulin delivery in pregnancy.
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Data points 1,923 966 957
Target range (70–180 mg/dL) 1,609 794 815
Hypoglycemia (,70 mg/dL) 247 132 115
Hyperglycemia (.180 mg/dL) 67 40 27
Mean absolute relative difference (%)
Overall 13.3 14.68 11.93 0.15
Target range 12.16 13.44 10.92
Hypoglycemia 21.91 23.70 19.84
Hyperglycemia 9.25 9.52 8.86
Median absolute relative difference (%)
Overall 11.42 12.85 9.89 0.21
Target range 10.46 12.07 8.99
Hypoglycemia 21.58 22.75 20.33
Hyperglycemia 9.06 9.27 8.73
International Standards Organization criteria*
Overall 79.62 76.40 82.86 0.33
Target range 81.54 78.21 84.79
Hypoglycemia 61.94 58.33 66.09
Hyperglycemia 98.51 100 96.30
Error grid analysis, %
A–Clinically accurate 78.94 75.75 82.45 0.55†
B–Within 20% of reference 15.70 17.90 13.17
C–Overcorrection error 0 0 0
D–Failure to detect hypoglycemic or
hyperglycemic excursion 5.36 6.35 4.39
E–Unsafe control 0 0 0
*International Standards Organization criteria are based on the percentage CGM measurements within 15
mg/dL from reference when the reference plasma glucose is #75 mg/dL or within 20% from reference when
the reference plasma glucose is .75 mg/dL. †P value refers to error grid analysis A + B combined values of
93.6% in early pregnancy vs. 95.6% in late pregnancy.
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Closed-loop in pregnancyperformed studies. A.H. and M.N. analyzed
data.H.R.M.,M.N.,andR.H.interpreteddata.
H.R.M. drafted the manuscript. R.T., D.E.,
M.E.W., D.S., D.B.D., and R.H. reviewed and
edited the manuscript. All authors approved
the ﬁnal version.
Interim data from this study (conﬁned only
to ﬁndings in early pregnancy) were presented
at the American Diabetes Association (26 June
2010), Diabetes UK (3 March 2010), and Ad-
vanced Technologies and Treatments for Di-
abetes (12 February 2010) meetings.
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